Overview

A Trial of MBC-11 in Patients With CIBD

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This study evaluates MBC-11 (a conjugate of a bone-targeting vehicle (etidronate) and a cytostatic agent [ara-C] in patients with malignant tumors with CIBD. This is a first use in human.

Phase:

Phase 1

Details

Lead Sponsor:

Osteros Biomedica Ltd